Zostavax shortage due to unexpected popularity

Reports have emerged two weeks after the shingles vaccine was added to the National Immunisation Program Zostavax is Australia’s only vaccine to protect against shingles and postherpetic neuralgia, and on 1 November was added to the National Immunisation Program for people aged 70-79. Supplier Seqirus has confirmed that due to the vaccine's unexpected popularity, it is temporarily experiencing

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy criticised as diabetes trial launches
Next Research roundup